论文部分内容阅读
分析该院1997年1月至2006年6月间收治的12例原发性食管小细胞癌(PESC)的临床资料、治疗和预后,并复习相关文献。结果:11例患者获得随访,中位生存期13个月,1年生存率为54.54%,无2年生存者。局限期11例中,7例采取以手术+化疗为基础的综合治疗,中位生存期为14个月;单一手术2例,分别生存12个月及8个月;单一化疗1例,生存期为11个月;另1例失访。广泛期1例,采取放疗+化疗进行综合治疗,生存期为9个月。结果表明:PESC的总体治疗效果及预后仍较差;包含化疗的综合治疗可以作为一种标准的治疗模式;以手术+化疗为基础的综合治疗可能是目前对局限期PESC的一种较好的治疗方式。
The clinical data, treatment and prognosis of 12 patients with primary esophageal small cell carcinoma (PESC) admitted from January 1997 to June 2006 in our hospital were analyzed. Relevant literatures were reviewed. Results: Eleven patients were followed up for a median of 13 months. The 1-year survival rate was 54.54%, with no 2-year survival. Of the 11 patients, 7 patients underwent combined surgery and chemotherapy. The median survival time was 14 months. In the single operation, 2 patients survived for 12 months and 8 months respectively. One patient received chemotherapy alone and the survival time For 11 months; the other one lost. A wide range of cases, to take radiotherapy + chemotherapy for comprehensive treatment, the survival of 9 months. The results showed that: the overall therapeutic effect and prognosis of PESC are still poor; the comprehensive treatment with chemotherapy can be used as a standard treatment model; combined surgery and chemotherapy based treatment may be the current one of the better for limited PESC treatment.